Merck & Co’s Keytruda immunotherapy has produced mixed results in a phase 3 trial testing it in first-line extensive-stage small cell lung cancer (SCLC).
Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.
AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.
The FDA has approved Merck's Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), after green-lighting Bristol-Myers Squibb’s (BMS)